MedPath

Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)

Completed
Conditions
Cardiovascular Event
Coronary Artery Bypass Graft
Diabetes Mellitus
Registration Number
NCT03590223
Lead Sponsor
University Hospital, Basel, Switzerland
Brief Summary

Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
589
Inclusion Criteria
  • patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012
Exclusion Criteria
  • disapproval of use of data for research purposes

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
occurence of Major adverse cardiac eventsperioperative = in hospital

myocardial infarction, cardiac related death, stroke

Secondary Outcome Measures
NameTimeMethod
occurence of severe renal insufficiencyperioperative = in hospital

application of renal replacement therapy (renal dialysis)

occurence of sternal wound infectionperioperative = in hospital

sternal wound infection

mortalityperioperative = in hospital

death rate perioperative

Trial Locations

Locations (1)

Herzchirurgie University Hospital Basel

🇨🇭

Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath